T2DM is usually treated with insulin sensitizers such as thiazolidinediones (TZDs) or insulin [76], although their adverse effects limit their long use, and the research on antidiabetic hypoglycaemic medicines is consistent. This evidence concerns the gene INS and type 2 diabetes mellitus.